BIO Praises 21st Century Cures Initiative discussion draft.
Share:
Press Release Summary:
BIO President and CEO Jim Greenwood recognized and thanked Committee on Energy and Commerce for its 21st Century Cures Initiative discussion draft, which intends to transform patient care by accelerating discovery, development, and delivery of next generation modern medicines. Greenwood noted several of BIO's suggestions within said draft and expressed support for provisions "intended to further incentivize biomedical innovation and help expedite the development of new treatments and cures."
Original Press Release:
BIO Praises the Release of the 21st Century Cures Initiative Discussion Draft
WASHINGTON – The Biotechnology Industry Organization (BIO) today releases the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI).
“We also strongly support provisions intended to further incentivize biomedical innovation and help expedite the development of new treatments and cures, particularly in areas of unmet medical need where existing incentives may be inadequate to drive sufficient investment.”
This statement can be attributed to Jim Greenwood, BIO President and CEO:
“Today, we recognize and thank the Committee on Energy and Commerce for releasing its 21st Century Cures Initiative discussion draft intended to accelerate the discovery, development and delivery of next generation modern medicines to transform patient care.
“Working with member companies, patient advocacy groups, and other stakeholders, we developed numerous proposals to create a public policy environment that encourages the use of 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to continuously develop and improve upon therapies that can prevent, diagnose and treat all stages of disease.
“We are pleased to see several of our priority suggestions in the discussion draft, including the need for a large-scale national research commitment to study precursors and signs of disease and disease risk factors for chronic conditions. Through the 21st Century Cures Initiative, we hope to work with the Congress, the NIH, and the patient community to develop a study that has the potential to revolutionize our understanding of disease, thus resulting in better treatments and cures.
“We also embrace the focus on precision medicine through genomics and regulatory science. Industrial scale biomarker qualification and full genome sequencing will help us better understand the molecular basis of disease and develop precision therapies tailored to each patient.
“We believe that placing patients at the center of the drug development process will spur the development of therapies for the most prevalent conditions, as well as encourage development of treatments focused on unmet medical needs. We strongly support establishing a framework for incorporating patient views into the development and regulatory review process in a more structured and transparent way, with respect to benefit-risk assessments and use of patient experience data.
“Further, we support modernizing clinical trials to expedite and accelerate drug development through the use of alternative clinical trial designs, biomarkers and surrogate endpoints, and modern scientific approaches and greater utilization of post-market validation and other confirmatory techniques, including the use of real-world data.
“We also strongly support provisions intended to further incentivize biomedical innovation and help expedite the development of new treatments and cures, particularly in areas of unmet medical need where existing incentives may be inadequate to drive sufficient investment.
“In addition, we support enhancing the Food and Drug Administration’s scientific capacity by improving access to adequate funding, recruiting world-class scientific and technical experts, and expanding management processes and human resource functions to meet the complexities of 21st Century scientific discovery.
“While we are still reviewing the many proposals contained within the discussion draft, we look forward to working with Chairman Upton and Rep. DeGette to ensure that the 21st Century Cures Initiative expedites the delivery of the next generation of modern medicines that will save lives and reduce and eliminate suffering.”
For more information on BIO and the biotechnology industry organization, please visit www.bio.org.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY
BIO-Europe Spring
March 9-11, 2015
Paris, France
BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan
BioEquity Europe
May 19-20, 2015
Vienna, Austria
BIO International Convention
June 15-18, 2015
Philadelphia, PA
Contacts
Biotechnology Industry Organization
Tracy Cooley, APR
202-312-9274
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
